CSClaire Snyder

Claire Snyder

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Claire Snyder has a total of 354 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association of Care Coordination and Discontinuity With Patterns of Care and Outcomes in Childhood Cancer Survivors With Multiple Chronic Conditions: A Report From the Childhood Cancer Survivor Study

    by Claire Snyder, Rebecca Eary, Wendy M. Leisenring, Kayla L. Stratton, Cynthia M. Boyd, Lorraine T. Dean, Melissa M. Hudson, Eric J. Chow, Kevin C. Oeffinger, Elyse R. Park, et al.

    Introduction: Given the substantial chronic condition burden among adult survivors of childhood cancer, we explored associations between care coordination and discontinuity with patterns of care and health status. Methods: Data from Childhood Cancer Survivor Study (CCSS) participants with multiple chronic conditions who completed the validated CC‐MC measure of care coordination and discontinuity in 2022 were linked with data from 2019 to 2021 on emergency department [ED] visits, hospitalizations, risk‐based survivorship care advice, recommended screenings, and health status (SF‐36, Brief Symptom Inventory [BSI‐18]). Independent variables included three CC‐MC coordination summary scores: main provider (knowing the patient and coordinating their care), multiple provider (coordinating care within and across clinics), patient‐provider partnership (explaining things, considering patient goals); and discontinuity (dichotomous). Adjusted generalized linear models estimated prevalence ratios (PR), rate ratios (RR), and beta coefficients. Results: Participants ( n = 365) were mean age 48.2 years, 68.5% female, 90.1% non‐Hispanic White. Better main provider (RR = 0.87; 95% CI: 0.77–0.99) and multiple provider (RR = 0.85; 95% CI: 0.80–0.90) scores were associated with less ED use; better multiple provider scores with fewer hospitalizations (RR = 0.88; 95% CI: 0.81–0.96); and better patient‐provider partnership scores with receiving risk‐based survivorship care advice (PR = 1.04; 95% CI: 1.01–1.08). We found no consistent associations between CC‐MC scores and recommended screening, though screening rates were generally high. All three CC‐MC summary scores were associated with fewer BSI global severity score elevations (PR range: 0.62–0.84). Discontinuity was associated with more hospitalizations (RR = 1.61; 95% CI: 1.03–2.51) and BSI global severity score elevations (PR = 4.20; 95% CI: 1.74–10.16). Conclusion: Promoting care coordination across multiple providers and improving continuity may improve care and outcomes in this vulnerable population.

  • Open Access

    Data from Weight Loss Responses to Pharmacotherapy in Breast Cancer Survivors: Results from the Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study

    by Jennifer Y. Sheng, Marianna L. Zahurak, Faith Too, Amanda Montanari, Jennifer Trost, Mengyang Lu, Young Lee, Sheetal Parida, Amanda L. Blackford, Dipali Sharma, et al.

    Purpose:Behavioral weight loss (BWL) interventions consisting of remote coaching and self-monitoring have limited effectiveness in breast cancer survivors. We conducted a single-arm phase II study evaluating the addition of Contrave for <5% weight loss (%WL) after 2 months of BWL. Patients and Methods:Women with prior stage 0 to III breast cancer and a body mass index ≥27 kg/m2 were eligible and initiated BWL. We collected weight, patient-reported outcomes, and labs at baseline, 2 months, and 6 months. At 2 months, participants with ≥5% WL (FAST-BWL) continued BWL, whereas those with <5% WL (SLOW-BWL) received BWL + Contrave. The primary endpoint was the proportion of SLOW-BWL with ≥5% WL at 6 months, with 30 participants providing 80% power with 5% type I error. Paired t tests, Kruskal–Wallis tests, and mixed-effects models were utilized. Results:Of 55 participants, 2 withdrew prior to 2 months. At 2 months, 15 (28.3%) were FAST-BWL with mean% WL [standard deviation (SD)] of 7.2% (1.5) and 38 (71.7%) were SLOW-BWL with mean% WL (SD) of 1.2% (2.2). Mean% WL between 2 and 6 months was similar in SLOW-BWL (3.8% ± 3.6) and FAST-BWL (3.6% ± 2.6). At 6 months, mean% WL (SD) was 5.1% (2.9) for SLOW-BWL and 10.8% (3.5) for FAST-BWL; 13 of 15 (86.7%) FAST-BWL and 16 of 38 (42%) SLOW-BWL had ≥5% WL. Physical function and pain improved with ≥5% WL (P = 0.03 and P = 0.02, respectively). SLOW-BWL had improved HbA1c (P = 0.003) and triglycerides (P = 0.04). Gastrointestinal symptoms were reported in 74% of SLOW-BWL. Of 6 withdrawals on Contrave, 1 was due to adverse events. Conclusions:Adding Contrave for breast cancer survivors with minimal initial benefit from BWL results in clinically meaningful WL (≥5%) in 42% following 6 months of treatment, which also improves selective cardiometabolic risk factors.

  • Open Access

    Supplementary Data 1 from Weight Loss Responses to Pharmacotherapy in Breast Cancer Survivors: Results from the Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study

    by Jennifer Y. Sheng, Marianna L. Zahurak, Faith Too, Amanda Montanari, Jennifer Trost, Mengyang Lu, Young Lee, Sheetal Parida, Amanda L. Blackford, Dipali Sharma, et al.

    Includes 5 tables and 3 figures

  • Open Access

    Weight Loss Responses to Pharmacotherapy in Breast Cancer Survivors: Results from the Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study

    by Jennifer Y. Sheng, Marianna L. Zahurak, Faith Too, Amanda Montanari, Jennifer Trost, Mengyang Lu, Young Lee, Sheetal Parida, Amanda L. Blackford, Dipali Sharma, et al.

    Purpose: Behavioral weight loss (BWL) interventions consisting of remote coaching and self-monitoring have limited effectiveness in breast cancer survivors. We conducted a single-arm phase II study evaluating the addition of Contrave for <5% weight loss (%WL) after 2 months of BWL. Patients and Methods: Women with prior stage 0 to III breast cancer and a body mass index ≥27 kg/m2 were eligible and initiated BWL. We collected weight, patient-reported outcomes, and labs at baseline, 2 months, and 6 months. At 2 months, participants with ≥5% WL (FAST-BWL) continued BWL, whereas those with <5% WL (SLOW-BWL) received BWL + Contrave. The primary endpoint was the proportion of SLOW-BWL with ≥5% WL at 6 months, with 30 participants providing 80% power with 5% type I error. Paired t tests, Kruskal–Wallis tests, and mixed-effects models were utilized. Results: Of 55 participants, 2 withdrew prior to 2 months. At 2 months, 15 (28.3%) were FAST-BWL with mean% WL [standard deviation (SD)] of 7.2% (1.5) and 38 (71.7%) were SLOW-BWL with mean% WL (SD) of 1.2% (2.2). Mean% WL between 2 and 6 months was similar in SLOW-BWL (3.8% ± 3.6) and FAST-BWL (3.6% ± 2.6). At 6 months, mean% WL (SD) was 5.1% (2.9) for SLOW-BWL and 10.8% (3.5) for FAST-BWL; 13 of 15 (86.7%) FAST-BWL and 16 of 38 (42%) SLOW-BWL had ≥5% WL. Physical function and pain improved with ≥5% WL (P = 0.03 and P = 0.02, respectively). SLOW-BWL had improved HbA1c (P = 0.003) and triglycerides (P = 0.04). Gastrointestinal symptoms were reported in 74% of SLOW-BWL. Of 6 withdrawals on Contrave, 1 was due to adverse events. Conclusions: Adding Contrave for breast cancer survivors with minimal initial benefit from BWL results in clinically meaningful WL (≥5%) in 42% following 6 months of treatment, which also improves selective cardiometabolic risk factors.

  • Open Access

    From framework to practice: applying the proteus-practice framework to learn lessons for integrating PROs in clinical care

    by Anne L R Schuster, Claire Snyder, Lotte Haverman, Jennifer R Cracchiolo, Liv Marit Valen Schougaard, Amy M Cizik, Alex Tarlochan Singh Sandhu, Michael Brundage, Norah L Crossnohere

    Purpose: As the use of patient-reported outcomes (PROs) in clinical practice expands, there is a growing need to understand how PROs are being integrated across diverse healthcare settings. We aimed to use the PROTEUS-Practice Framework to systematically describe real-world approaches to PRO integration into clinical care and identify lessons learned. Methods: Participants in the international PROTEUS Consortium were invited to submit case studies describing PRO applications in clinical care. Contributors completed a structured template aligned with the PROTEUS-Practice Framework, which outlines 16 steps for PRO integration across design, implementation, and management stages. Case studies were descriptively summarized by framework step and responses were thematically analyzed by framework stage to identify lessons learned. Results: Five case studies described the integration of PROs in diverse clinical contexts, including three within individual health systems and two spanning multiple health systems. Fifteen cross-cutting lessons learned emerged across the PROTEUS-Practice Framework stages. Themes identified in at least three case studies include the importance of stakeholder training during design, PRO champions during implementation, and EHR integration to support management. Clear goals, alignment of expected outcomes, iterative design processes, user-friendly visualizations, and regular system updates were also commonly emphasized as critical to successful integration. Conclusion: The PROTEUS-Practice Framework provided a structured approach for describing real-world approaches to PRO integration in clinical care. Its use enabled the identification of cross-cutting lessons learned that offer practical guidance for optimizing PRO integration and tailoring its use in diverse clinical contexts.

  • Benefits of Electronic Symptom Monitoring During Cancer Treatment by Age, Sex, Race, and Education (Alliance AFT-39)

    by Allison M. Deal, Yashasvini Sampathkumar, Brenda F. Ginos, Gina L. Mazza, Deborah Schrag, Jennifer Jansen, Angela M. Stover, Philip M. Carr, Patricia A. Spears, Mattias Jonsson, et al.

    PURPOSE: Remote symptom monitoring using patient-reported outcomes (PROs) has been shown to improve symptom control and physical function among patients with advanced cancer. However, it is unclear whether these benefits are similar across demographic groups. This exploratory analysis of the PRO-TECT trial examined whether the effects of electronic symptom monitoring varied by race, age, sex, and educational attainment. METHODS: PRO-TECT was a cluster randomized trial conducted across 52 US community oncology practices comparing weekly electronic symptom monitoring with usual care (UC). Adult patients with metastatic solid tumors receiving systemic therapy were enrolled (N = 1,191). Participants in the PRO arm completed weekly symptom surveys including the PRO-CTCAE, triggering alerts to the care team for severe or worsening symptoms. Patients chose whether to complete weekly PROs online or via telephone-based interactive voice response not requiring Internet access. Outcomes were measured using the European Organisation for Research and Treatment of Cancer QLQ-C30 symptom control and physical function scales. Subgroup analyses were performed by race (Black v White), age (high school). RESULTS: From baseline to 3 months, PRO participants showed greater improvements in symptom control (+2.37 v −0.20, P = .002) and physical function (+1.54 v −0.93, P = .02) versus UC. Benefits were most pronounced among younger, female, Black, and less educated participants. Black participants in the PRO arm were more likely to report that symptom reporting made them feel more in control of their care compared with White participants. CONCLUSION: Electronic symptom monitoring improved quality-of-life outcomes overall, including among groups who have historically experienced higher symptom burden or barriers to communication. Remote PRO systems may represent an equitable strategy to enhance cancer care delivery.

  • Open Access

    Do non-responders of a geriatric screening questionnaire face lower one-year survival compared to responders? A retrospective cohort study

    by Kathrine Hønholt Carlson, Lone Duval, Birgith Engelst Grove, Christina Bach Menzel, Claire Snyder, Jesper Ryg, Jonas Hermann Schrøder, Olalekan Lee Aiyegbusi, Regine Grytnes, Liv Marit Valen Schougaard

    Purpose: A geriatric screening questionnaire was implemented in 2020 at the Department of Oncology, Gødstrup Hospital, Denmark, to identify frailty and individualize cancer care for all patients aged ≥ 60 years. However, not all patients answered. The primary aim of this study was to investigate the association between response status to the geriatric screening questionnaire and one-year survival. A secondary aim was to compare one-year survival according to the responders’ frailty status. Methods: We conducted a retrospective cohort study including all patients with cancer aged ≥ 60 who were enrolled in the geriatric screening between August 2020 and October 2023. The survival curves for responders and non-responders and across the patients’ frailty status were visualized using Kaplan–Meier plots. The associations were analyzed using logistic regression adjusted for potential confounders. Results: In total, 702 patients were included. Among these, 28.1% were non-responders, 46.7% were classified as high risk of frailty, and 25.2% as low risk of frailty. The non-responders had the lowest survival, which declined rapidly in the first 100 days. Survival was similarly lower among non-responders and responders at high risk of frailty, compared to responders at low risk. When adjusted for cohabiting status, age, and cancer type, the odds ratio of survival among non-responders compared to responders was 0.63 (95%CI: 0.42;0.92). Conclusion: The non-responders had the lowest survival, comparable to patients at high risk of frailty among the responders. Their survival declined rapidly suggesting that non-response may signal vulnerability and warrant closer clinical attention or early supportive care.


  • Top Cited Papers
    Open Access

    International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROR

    by Emily Alger, Olalekan Lee Aiyegbusi, Amylou C. Dueck, Anna Minchom, Madeline Pe, John D. Peipert, Claire Snyder, Stefan N. Symeonides, Roger Wilson, Ethan Basch, et al.

    PURPOSE: There is growing scientific interest in incorporating patient-reported outcomes (PROs) in early phase dose-finding oncology trials (DFOTs) to assess tolerability, inform dose selection, and guide later stage trial design. However, research indicates that PRO objectives in DFOTs are often unclear. The Incorporating Patient-Reported Outcomes in Dose-Finding Trials-Research Objectives Recommendations (OPTIMISE-ROR) project was established to support trialists to effectively incorporate PROs into DFOTs. METHODS: Using the Enhancing Quality and Transparency of Health Research (EQUATOR) Network's methodological framework, guideline development included the following: (1) a methodological review of published DFOTs incorporating PROs; (2) candidate item generation, refined through expert consultation; (3) a two-round international multistakeholder Delphi survey (N = 109 in Round 1 [October 2024]; N = 96 in Round 2 [December 2024]); and (4) an independently chaired virtual consensus meeting (N = 31; January 2025) where multidisciplinary, international experts reviewed and voted to finalize items for inclusion. RESULTS: Consensus was reached on six recommendations emphasizing three core PRO tolerability concepts: overall side effect impact, symptomatic adverse events, and overall health-related quality of life. The integration of PROs to inform final dose recommendations in dose escalation and optimization trials should be considered, regardless of trial design. The recommendations highlight the importance of PRO data analysis over time and across dose levels, defining PRO research objectives as descriptive or statistically powered, and assessing PRO-related end points to guide end point selection for subsequent studies. CONCLUSION: This foundational guidance outlines key PRO research objectives in DFOTs. By facilitating the systematic integration of PROs, this guidance supports the utilization of patient-centered evidence for the tolerability and efficacy assessment of therapies to inform dose escalation, optimization, and regulatory evaluation—ultimately contributing to the development of safer, more effective therapies.


  • Open Access

    Neurocognitive impairment and financial hardship in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study

    by Daniel J Zheng, Shalini Bhatia, Sedigheh Mirzaei, Richard Aplenc, Gregory T Armstrong, Kira Bona, Tara M Brinkman, Pim Brouwers, Kim Edelstein, Kelly D Getz, et al.

    More than 60% of adult survivors of childhood cancer report medical financial hardship due to the cumulative costs of cancer-directed therapy and related chronic health conditions. Whether neurocognitive impairment as a late effect is associated with increased financial hardship is unknown. In a large national cohort of 3023 adult survivors of childhood cancer, we observed a dose-dependent relationship between neurocognitive impairment and financial hardship outcomes. Individuals with 4 impaired neurocognitive domains had over 3-fold increased odds of debt collection (odds ratio [OR] = 3.12, 95% confidence interval [CI] = 1.91 to 5.09) and bankruptcy (OR = 3.77, 95% CI = 2.01 to 7.07) compared to individuals with no impaired neurocognitive domains. After adjusting for education, employment, and household income, the independent association between neurocognitive impairment and financial hardship outcomes persisted suggesting that other mechanisms may be at play. Neurocognitive impairment is an important risk factor for medical financial hardship in this patient population and should be considered for targeted screening and intervention.


  • Health Outcomes Beyond Age 50 Years in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study

    by Rusha Bhandari, Yan Chen, Eric J. Chow, Rebecca M. Howell, Lisa B. Kenney, Kevin R. Krull, Wendy Leisenring, Paul C. Nathan, Joseph P. Neglia, Kirsten K. Ness, et al.

    PURPOSE: There are limited data on the risk for mortality and health outcomes among the increasing population of older (age >50 years) survivors of childhood cancer during this later stage in life when there is an expected increase in aging-related morbidities. METHODS: We assessed cause-specific mortality, incident new cancers, chronic health conditions (CHCs), frailty, and health status among survivors from the Childhood Cancer Survivor Study, conditional on surviving to 50 years. We calculated conditional survival rates, standardized mortality ratios (SMRs), and, for incident new cancers, cumulative burden, standardized incidence ratios (SIRs), and relative rates (RRs), compared with the general US population. RRs for CHCs and prevalence ratios for frailty and health status outcomes were calculated for survivors compared with siblings. Piecewise exponential regression identified risk factors. RESULTS: Among 7,490 childhood cancer survivors alive at age 50 years, subsequent 5-, 10-, and 15-year mortality risks were 8%, 18%, and 32%, respectively; overall SMR was 3.2 (95% CI, 3.0 to 3.4). SMRs were highest for death due to new cancer (SMR = 4.7; 95% CI, 4.2 to 5.2). In subset analysis, survivors without radiation therapy (RT) exposure had similar new cancer rates as the general population. The population attributable fraction of new cancers to RT was 40%. Survivors had >2-fold risk of severe, life-threatening, or fatal CHCs (any: RR, 2.6 [95% CI, 2.2 to 3.1]; multiple: RR, 3.3 [95% CI, 2.5 to 4.4]), specifically among survivors with history of RT exposure, compared with siblings. We identified no associations between chemotherapy and late health outcomes. CONCLUSION: Older survivors of childhood cancer continue to have an elevated burden of premature mortality, new cancers, and adverse health outcomes as they age. The increased risk for cancer and CHCs among these older survivors is associated with RT, but not chemotherapy, exposure.